|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||4.0244 - 4.0244|
|52-week range||4.0244 - 6.1000|
|Beta (5Y monthly)||0.47|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces it has initiated a new pharmaceutical development project, OX640, a nasal adrenaline product for the emergency treatment of allergic reactions.
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today provides information about its new proprietary drug delivery platform, amorphOXTM, a novel and inventive powder-based technology with significant potential. Several new patent applications directed to amorphOXTM have now been filed, which should serve to protect the technology until 2042.
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the company has successfully completed the pivotal trial (OX124-002) for its lead pharmaceutical pipeline asset, OX124. The study met its primary endpoints with naloxone exposure within the targeted interval. OX124 showed a significantly faster and higher absorption of naloxone compared to intramuscular dosing with the injection reference product. Furthermore, OX124 was found to be well tolerated. Based on the successful outcome of t